(Q35143905)

6 August 2017

1 reference

title

Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects (English)

1 reference

6 August 2017

author

Barbara Mary Fingleton

object named as

Barbara Fingleton

series ordinal

1

1 reference

ORCID Public Data File 2021

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Therapeutic Targets

6 August 2017

published in

1 reference

6 August 2017

volume

7

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

385-397

1 reference

New functions for the matrix metalloproteinases in cancer progression

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Matrix metalloproteinases: they're not just for matrix anymore!

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Metastatic potential correlates with enzymatic degradation of basement membrane collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Changing views of the role of matrix metalloproteinases in metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Ongoing trials with matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

In vivo molecular target assessment of matrix metalloproteinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

In vivo visualization of gene expression using magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Soluble E-cadherin is a valid prognostic marker in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Protease degradomics: a new challenge for proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Insights into cancer from transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

The promise and peril of surrogate end points in cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Matrix metalloproteinases: biologic activity and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Regulatory considerations for preclinical development of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

The ADAMs family of metalloproteases: multidomain proteins with multiple functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

ADAMTS: a novel family of extracellular matrix proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Evaluation of some newer matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Tumor targeting with a selective gelatinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Strategies for MMP inhibition in cancer: innovations for the post-trial era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.7.3.385

21 January 2018

Identifiers

DOI

10.1517/14728222.7.3.385

1 reference

6 August 2017

1 reference